Biomarker study to guide treatment for several advanced cancers
Part of Cancer, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study measures how strongly your immune system is being suppressed and uses that information to help personalize cancer treatment. It mainly looks at people with certain advanced cancers and needs tumor tissue and follow-up to check possible immune-related markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers: melanoma, hormone-resistant breast cancer, kidney cancer (RCC), bladder cancer (UC), head and neck squamous cancer (SCCHN), squamous or non-small cell lung cancer (SCC/NSCLC), or stage III resectable NSCLC
- You are 18 to 90 years old and can understand and sign the informed consent
- You can follow the study plan and come back regularly for visits at the same study center
- You can provide an existing tumor tissue sample (FFPE tissue from past biopsy/surgery) for extra testing
- Your overall health is good enough for study participation (ECOG 0–2)
- You agree to complete a short socio-economical/psychological questionnaire survey
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This trial is looking at a protein called CD160 on immune cells (NK cells) in melanoma patients. The goal is to understand if this protein can be a target for new treatments. By studying your blood and tumor samples, researchers hope to find better ways to treat advanced melanoma.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This study looks at how the bacteria in your gut might affect how well immunotherapy works for certain cancers. It is for people with advanced lung cancer, melanoma, or certain gynecologic cancers who are about to start immunotherapy, and it may help doctors understand why some people respond better than others.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
This study is looking at biomarkers (clues in your blood and tumor) to better understand how advanced lung cancer responds to immunotherapy. It aims to help doctors predict which treatments might work best for you in the future.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.